Silo Pharma, Inc. 8-K

What Happened
Silo Pharma, Inc. (ticker: SILO) filed an 8-K on December 29, 2025, reporting that Nasdaq granted the company a second 180‑calendar‑day extension to regain compliance with the minimum $1.00 per-share bid-price requirement under Nasdaq Listing Rule 5550(a)(2). The company had initially been given until December 24, 2025 to cure the deficiency but was unable to do so; Nasdaq’s Extension Notice extends the cure period through June 22, 2026. Nasdaq’s decision was based on Silo meeting other listing requirements except the bid price, and on the company’s notice that it may cure the deficiency, including by effecting a reverse stock split if necessary.

Key Details

• Nasdaq Listing Rule 5550(a)(2) requires a minimum closing bid of $1.00; a deficiency occurs after 30 consecutive business days below that threshold (Rule 5810(c)(3)(A)).
• Initial cure deadline: December 24, 2025; extension granted on December 24, 2025 for an additional 180 days, new deadline June 22, 2026.
• If the stock closes at or above $1.00 for 10 consecutive business days before June 22, 2026, Nasdaq will consider the company back in compliance.
• The Extension Notice does not affect current listing or trading; SILO will continue to trade on The Nasdaq Capital Market. If compliance is not demonstrated by June 22, 2026, Nasdaq may delist the common stock (subject to the company’s right to appeal). The company said it may consider options such as a reverse stock split.

Why It Matters
This filing signals a continued listing risk: if Silo Pharma does not restore its stock price above $1.00 for the required period by June 22, 2026, Nasdaq could move to delist the shares, which would likely reduce liquidity and could affect investor access to the stock. The company has time and stated options (including a possible reverse split) to regain compliance, and trading remains normal for now. Investors should monitor the company’s closing bid price and any corporate actions (e.g., reverse split) or further announcements related to Nasdaq compliance.